BG
ADMS

BlackRock Group’s Adamas Pharmaceuticals ADMS Stock Holding History

BlackRock Group’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-5,864
Closed -$154K – 3105
2015
Q2 		$154K Hold
5,864
– – ﹤0.01% 2646
2015
Q1 		$103K Buy
+5,864
New +$100K ﹤0.01% 2651
2014
Q4 		– Sell
-47,800
Closed -$890K – 2928
2014
Q3 		$890K Hold
47,800
– – ﹤0.01% 1856
2014
Q2 		$874K Buy
+47,800
New +$856K ﹤0.01% 1919

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CPH
C Partners Holding Zurich, Switzerland $317M AUM 4.76% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Group's ADMS Position: Q3 2015 in Review

BlackRock Group sold out of Adamas Pharmaceuticals (ADMS) in Q3 2015, closing a stake of 5,864 shares — an estimated $154K sold.

BlackRock Group first reported a position in ADMS in Q2 2014 and held it in 4 quarters. The position peaked at $890K in Q3 2014. 83 funds tracked by Wall St. Rank hold ADMS as of Q3 2015.

  • BlackRock Group reported no remaining Adamas Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • BlackRock Group sold 5,864 Adamas Pharmaceuticals shares in Q3 2015, an estimated $154K.
  • BlackRock Group first reported a position in Adamas Pharmaceuticals in Q2 2014 and held it in 4 quarters.
  • BlackRock Group's Adamas Pharmaceuticals position peaked at $890K in Q3 2014.
  • 83 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2015.

Based on BlackRock Group's 13F filing for Q3 2015, filed 13 Nov 2015.